Status:
COMPLETED
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
Lead Sponsor:
European Institute of Oncology
Conditions:
Cardiotoxicity
Chemotherapeutic Toxicity
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the...
Eligibility Criteria
Inclusion
- Consecutive patients undergoing high-dose chemotherapy showing early release of Troponin I
Exclusion
- Contraindication to ACE-inhibitors
- On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT00292526
Start Date
November 1 2000
End Date
November 1 2011
Last Update
February 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
European Institute of Oncology
Milan, Italy, 20141